Abstract
See page [1173][1] With the identification of tumor-associated antigens more than 30 y ago and the development of hybridoma technology in 1975, investigators realized that Paul Ehrlich's vision to effectively target drugs to diseased tissues could be tested. It was shown that monoclonal antibodies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
